Abstract
This study aimed to identify alternative intramuscular injection sites for ceftiofur in olive flounder (Paralichthys olivaceus) that maintain therapeutic efficacy and residue compliance while mitigating injection-site lesions in the edible dorsal fillet, which can reduce consumer acceptance despite short regulatory withdrawal periods. Following a single 10 mg/kg dose at four sites (dorsal, tail, cheek, pectoral fin) under two temperatures (23 °C, 13 °C), HPLC–MS/MS quantified exposure and residue depletion; PK/PD indices and withdrawal times were integrated with histopathology. %T>MIC exceeded β-lactam thresholds in most conditions, with the exception of pectoral fin at 13 °C (32.7% assuming MIC = 1 µg/mL). Dorsal injection at 23 °C met the 7-day withdrawal period, whereas non-dorsal sites exceeded this limit at the 99% tolerance level. Histopathology revealed lesions persisting to 168 h post-injection at all sites, underscoring marketability concerns for edible fillet. Collectively, tail muscle demonstrated relatively stable pharmacokinetics across temperatures and may represent a viable alternative injection site; however, an extended withdrawal period beyond the currently approved 7 days would be required for regulatory compliance at 23 °C. Dorsal injection provides the best balance of efficacy and regulatory compliance. These findings support site-specific dosing guidance to optimize outcomes and consumer acceptance.

This publication has 12 references indexed in Scilit: